MedCity Autumn Investment Hub 2021

Six early stage companies having a direct or indirect impact on patients will be presenting their breakthrough business and products.

Agenda

3pm – Welcome MedCity

Guest Speakers-

Peter Finnie- Potter Clarkson

Filippo Falaschi- Spex Capital

3.15- 4pm- Three Company Pitches (10 minute pitches followed by 5 minute Q&A)

following a 5 minute break

4.05-4.50 pm- Three Company Pitches (10 minute pitches followed by 5 minute Q&A)

4.50-5pm Wrap up and Close

5-5.30– Virtual Networking TBC – If anyone would like to stay online and speak further with any of the presenting companies this can be arranged in virtual breakout rooms

Hear from:

• A company providing a B2B SAAS platform that automates protocols in safety-critical industries using AI-driven event detection that integrates data from sensors, existing datasets, ML models They currently focus on inventory management in surgery. They have already secured 2/3 of the current round of funding with a lead investor in place.

• A B2B telehealth company that provides a hearing healthcare platform to enable those with hearing loss. An enhanced, personalised audio stream is delivered specific to an individual’s hearing needs. With a substantial market size, this proven technology is a CE marked device due to its diagnostics capabilities, with a MVP in operation and significant partnerships under discussion.

• A revolutionary biotech spin-out from the University of Exeter with an Oxford-based management team. Their mitochondrial-protective drugs are in early development for Duchenne muscular dystrophy (DMD), a rare metabolic disease (CBS-deficiency) and dementia. They have already shown efficacy in reversing loss of muscle strength and functional neuroprotection in animal models Likely to partner early in neurodegeneration and out-license further non-core indication rights.

• A company that has developed a proprietary platform technology offering revolutionary new molecular detection. Having already demonstrated this highly sensitive detection method for non-medical uses they are looking at how they can use this technology in rapid diagnosis of diseases, including sampling of exhaled breath for infectious disease.

• A biotech start-up developing universal genomic screening for cardiovascular diseases using RNA sequencing and machine learning. Bringing liquid biopsy to cardiovascular disease. They have a proprietary laboratory validated prototype, and are conducting pilot clinical trials aiming to achieve initial clinical validation of their whole-blood liquid biopsy approach in the cardiovascular space.

• A seed-stage MedTech start-up that has developed a wearable augmented reality medical device (glasses) to alleviate and treat motor symptoms in Parkinson’s Disease. After 2.5 years of development, the company is experiencing rapid growth having recently been awarded a significant government grant. Already gaining commercial traction. Published in numerous journals and accepted onto the Microsoft for start up’s programme. 2/3 of the round already committed.

Investors: Registration for the event is open to qualified investors only. If you are an investor interested in joining the network, please contact Sarah Bruce-White, Partnerships and Programmes Lead at sarahbrucewhite@medcityhq.com.

If you are already a member of the MedCity Investment Hub, details for registration will be sent to you directly.